Dual B-cell targeting therapy ameliorates autoimmune cholangitis.

ABSTRACT:

Objective

The ability to regulate B cell development has long been recognized to have therapeutic potential in a variety of autoimmune diseases. However, despite the presence of a classic autoantibody in primary biliary cholangitis (PBC), B cell depleting therapy and indeed therapy with other biologic agents has been disappointing. Unsuccessful treatment using Rituximab is associated with elevation of B-cell activating factor (BAFF) level. Indeed, therapies for PBC remain directed at modulating bile salt biology, rather than targeting effector pathways. With these data in mind, we proposed that targeting two major stages of B cell development, namely long-lived memory B cells and short-lived peripheral autoreactive plasma cells would have therapeutic potential.

Methods

To ad

SUBMITTER: Zhang W 

PROVIDER: S-EPMC10311358 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature